Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malaria
  Free Subscription

Articles published in
Vaccine
    July 2024
  1. CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
    Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
    Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
    >> Share

    May 2024
  2. MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
    Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
    Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  3. LAMBACH P, Silal S, Sbarra AN, Koh M, et al
    Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
    Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
    >> Share

    April 2024
  4. CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
    A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
    Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
    >> Share

    March 2024
  5. MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
    Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
    Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
    >> Share

    February 2024
  6. PLIESKATT J, Bang P, Wood GK, Naghizadeh M, et al
    Clinical formulation development of Plasmodium falciparum malaria vaccine candidates based on Pfs48/45, Pfs230, and PfCSP.
    Vaccine. 2024 Feb 21:S0264-410X(24)00202-0. doi: 10.1016/j.vaccine.2024.
    >> Share

  7. FABER BW, Yeoh LM, Kurtovic L, Mol WEM, et al
    A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies.
    Vaccine. 2024 Feb 16:S0264-410X(24)00175-0. doi: 10.1016/j.vaccine.2024.
    >> Share

    November 2023
  8. MOITA D, Nunes-Cabaco H, Rola C, Franke-Fayard B, et al
    Variable long-term protection by radiation-, chemo-, and genetically-attenuated Plasmodium berghei sporozoite vaccines.
    Vaccine. 2023 Nov 24:S0264-410X(23)01335-X. doi: 10.1016/j.vaccine.2023.
    >> Share

  9. HAYASHI CTH, Cao Y, Zavala F, Simonyan H, et al
    Antibodies elicited by Plasmodium falciparum circumsporozoite proteins lacking sequentially deleted C-terminal amino acids reveal mouse strain and epitopes specific differences.
    Vaccine. 2023;41:6824-6833.
    >> Share

    August 2023
  10. SHEARS MJ, Watson FN, Stone BC, Cruz Talavera I, et al
    Preliminary studies on the immunogenicity of a prime-and-trap malaria vaccine in nonhuman primates.
    Vaccine. 2023 Aug 8:S0264-410X(23)00913-1. doi: 10.1016/j.vaccine.2023.
    >> Share

    May 2023
  11. SIMONS LM, Ferrer P, Gombakomba N, Underwood K, et al
    Extending the range of Plasmodium falciparum transmission blocking antibodies.
    Vaccine. 2023;41:3367-3379.
    >> Share

    April 2023
  12. TOPAZIAN HM, Schmit N, Gerard-Ursin I, Charles GD, et al
    Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
    Vaccine. 2023 Apr 18:S0264-410X(23)00394-8. doi: 10.1016/j.vaccine.2023.
    >> Share

    February 2023
  13. RANADE D, Jena R, Patil K, Dogar V, et al
    A novel high throughput plate-based method for 2-PE quantification in novel multidose vaccines (R21 malaria, Covishield and Covovax) and combination vaccines (Hexavalent).
    Vaccine. 2023 Feb 17:S0264-410X(23)00174-3. doi: 10.1016/j.vaccine.2023.
    >> Share

    January 2023
  14. KABIR SULAIMAN S, Isma'il Tsiga-Ahmed F, Sale Musa M, Kabir Sulaiman A, et al
    Prevalence, determinants, and reasons for malaria vaccine hesitancy among caregivers of under-five children in Nigeria: Results from a nationwide cross-sectional survey.
    Vaccine. 2023 Jan 30:S0264-410X(23)00089-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  15. BARAL R, Levin A, Odero C, Pecenka C, et al
    Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Vaccine. 2023 Jan 27:S0264-410X(23)00064-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  16. DEVECI G, Kamil M, Aly ASI
    A single dose of genetically-attenuated malaria blood-stage parasites protects against two Plasmodium species infections.
    Vaccine. 2023 Jan 16:S0264-410X(23)00003-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  17. BELMONTE M, Ganeshan H, Huang J, Belmonte A, et al
    Immunodominant T cell peptides from four candidate malarial antigens as biomarkers of protective immunity against malaria.
    Vaccine. 2023 Jan 13:S0264-410X(23)00027-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  18. BAI J, Liu F, Yang F, Zhao Y, et al
    Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.
    Vaccine. 2023;41:555-563.
    >> Share

    December 2022
  19. TOTTEY S, Shoji Y, Mark Jones R, Musiychuk K, et al
    Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate.
    Vaccine. 2022 Dec 28:S0264-410X(22)01573-0. doi: 10.1016/j.vaccine.2022.
    >> Share

    August 2022
  20. HUTTER JN, Robben PM, Lee C, Hamer M, et al
    First-in-human assessment of safety and immunogenicity of low and high doses of Plasmodium falciparum malaria protein 013 (FMP013) administered intramuscularly with ALFQ adjuvant in healthy malaria-naive adults.
    Vaccine. 2022 Aug 30. pii: S0264-410X(22)01039.
    >> Share

    June 2022
  21. SCHNEIDER CG, Fey J, Zou X, Gerbasi V, et al
    Norovirus-VLPs expressing pre-erythrocytic malaria antigens induce functional immunity against sporozoite infection.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00701.
    >> Share

    January 2022
  22. AREVALO-HERRERA M, Miura K, Solano E, Sebastian Ramirez J, et al
    Immunogenicity of full-length P. vivax rPvs48/45 protein formulations in BALB/c mice.
    Vaccine. 2022;40:133-140.
    >> Share

    December 2021
  23. KUSI KA, Ofori EA, Akyea-Mensah K, Kyei-Baafour E, et al
    Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana.
    Vaccine. 2021 Dec 27. pii: S0264-410X(21)01650.
    >> Share

  24. RANADE D, Jena R, Sancheti S, Deore V, et al
    Rapid, high throughput protein estimation method for saponin and alhydrogel adjuvanted R21 VLP Malaria vaccine based on intrinsic fluorescence.
    Vaccine. 2021 Dec 18. pii: S0264-410X(21)01627.
    >> Share

    September 2021
  25. MOON JE, Greenleaf ME, Regules JA, Debois M, et al
    A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01E in a controlled human malaria infection challenge.
    Vaccine. 2021 Sep 27. pii: S0264-410X(21)01203.
    >> Share

    June 2021
  26. DASSAH S, Adu B, Sirima SB, Mordmuller B, et al
    Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine.
    Vaccine. 2021 Jun 23. pii: S0264-410X(21)00760.
    >> Share

    April 2021
  27. VEKEMANS J, Schellenberg D, Benns S, O'Brien K, et al
    Meeting report: WHO consultation on malaria vaccine development, Geneva, 15-16 July 2019.
    Vaccine. 2021 Apr 27. pii: S0264-410X(21)00409.
    >> Share

  28. DE SL, May S, Shah K, Slawinski M, et al
    Variable immunogenicity of a vivax malaria blood-stage vaccine candidate.
    Vaccine. 2021 Apr 8. pii: S0264-410X(21)00376.
    >> Share

    February 2021
  29. DAS SC, Price JD, Gosling K, MacLennan N, et al
    Liposome engraftment and antigen combination potentiate the immune response towards conserved epitopes of the malaria vaccine candidate MSP2.
    Vaccine. 2021 Feb 20. pii: S0264-410X(21)00158.
    >> Share

    January 2021
  30. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Cox C, et al
    Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing.
    Vaccine. 2021 Jan 22. pii: S0264-410X(20)31590.
    >> Share

  31. CHAUDHURY S, MacGill RS, Early AM, Bolton JS, et al
    Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Vaccine. 2021 Jan 8. pii: S0264-410X(20)31635.
    >> Share

    December 2020
  32. SUAU R, Vidal M, Aguilar R, Ruiz-Olalla G, et al
    RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial.
    Vaccine. 2020 Dec 24. pii: S0264-410X(20)31606.
    >> Share

    October 2020
  33. MO AXY, Pesce J, Augustine AD, Bodmer JL, et al
    Understanding vaccine-elicited protective immunity against pre-erythrocytic stage malaria in endemic regions.
    Vaccine. 2020 Oct 15. pii: S0264-410X(20)31253.
    >> Share

  34. THOMPSON HA, Hogan AB, Walker PGT, White MT, et al
    Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31251.
    >> Share

  35. EZOE S, Palacpac NMQ, Tetsutani K, Yamamoto K, et al
    First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
    Vaccine. 2020 Oct 1. pii: S0264-410X(20)31227.
    >> Share

    September 2020
  36. VAN DER GRAAF R, Macklin R, Rid A, Bhan A, et al
    Integrating public health programs and research after the malaria vaccine implementation program (MVIP): Recommendations for next steps.
    Vaccine. 2020 Sep 24. pii: S0264-410X(20)31132.
    >> Share

    June 2020
  37. OUATTARA A, Niangaly A, Adams M, Coulibaly D, et al
    Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants.
    Vaccine. 2020 Jun 19. pii: S0264-410X(20)30821.
    >> Share

    May 2020
  38. ONEKO M, Cherop YR, Sang T, Gutman JR, et al
    Feasibility of direct venous inoculation of the radiation-attenuated Plasmodium falciparum whole sporozoite vaccine in children and infants in Siaya, western Kenya.
    Vaccine. 2020 May 19. pii: S0264-410X(20)30614.
    >> Share

    March 2020
  39. TACHIBANA M, Baba M, Takashima E, Tsuboi T, et al
    The C-terminal region of the Plasmodium yoelii microgamete surface antigen PyMiGS induces potent anti-malarial transmission-blocking immunity in mice.
    Vaccine. 2020;38:3129-3136.
    >> Share

    February 2020
  40. QIU Y, Zhao Y, Liu F, Ye B, et al
    Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine candidate.
    Vaccine. 2020 Feb 21. pii: S0264-410X(20)30184.
    >> Share

  41. SSEMAGANDA A, Giddam AK, Low LM, Liu XQ, et al
    Mannosylated liposomes formulated with whole parasite P. falciparum blood-stage antigens are highly immunogenic in mice.
    Vaccine. 2020;38:1494-1504.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016